Meyeon Park1, Chi-Yuan Hsu2, Alan S Go3, Harold I Feldman4, Dawei Xie4, Xiaoming Zhang4, Theodore Mifflin4, Sushrut S Waikar5, Venkata S Sabbisetti5, Joseph V Bonventre5, Josef Coresh6, Robert G Nelson7, Paul L Kimmel7, John W Kusek7, Mahboob Rahman8, Jeffrey R Schelling8, Ramachandran S Vasan9, Kathleen D Liu2. 1. Division of Nephrology, University of California, San Francisco, San Francisco, California; Meyeon.Park@ucsf.edu. 2. Division of Nephrology, University of California, San Francisco, San Francisco, California. 3. Division of Research, Kaiser Permanente Northern California, Oakland, California. 4. Department of Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 6. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland. 7. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 8. Division of Nephrology and Hypertension, Case Western Reserve University, Cleveland, Ohio; and. 9. Section of Preventive Medicine and Epidemiology, Boston University, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: CKD is an important risk factor for cardiovascular disease (CVD) and death. We investigated whether select urine kidney injury biomarkers were associated with higher risk of heart failure (HF), CVD, and death in persons with CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Urine kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin, liver fatty acid-binding protein, and N-acetyl-β-d-glucosaminidase were measured in urine of a subset of CRIC participants (n=2466). We used Cox proportional hazards regression to examine associations between these biomarkers indexed to urinary creatinine (Cr) and (1) HF, (2) a composite of atherosclerotic CVD events (myocardial infarction, ischemic stroke, or peripheral artery disease), and (3) all-cause death. RESULTS: At baseline, mean age of study participants was 59.5±10.8 years, 46% were women, and 34% had a self-reported history of any CVD. Median follow-up was 6.5 (interquartile range, 5.6-6.8) years. A total of 333 HF events, 282 atherosclerotic CVD events, and 440 deaths were observed during a median follow-up of 6.5 (interquartile range, 5.6-6.8) years. Those in the highest two quintiles of KIM-1/Cr levels had a higher risk of HF relative to the lowest quintile (quintile 5 versus quintile 1 adjusted hazard ratio [aHR] of 1.73 [95% confidence interval, 1.05 to 2.85]). N-acetyl-β-d-glucosaminidase/Cr was associated with HF in continuous analyses (aHR per log SD higher 1.18 [95% confidence interval, 1.01 to 1.38]). Only KIM-1/Cr was independently associated with atherosclerotic CVD events (aHR per log SD higher 1.21 [95% confidence interval, 1.02 to 1.41]), whereas both KIM-1/Cr (quintile 5 versus quintile 1 aHR of 1.56 [95% confidence interval, 1.06 to 2.31]) and neutrophil gelatinase-associated lipocalin/Cr (quintile 5 versus quintile 1 aHR of 1.82 [95% confidence interval, 1.19 to 2.8]) were associated with all-cause death. CONCLUSIONS: Selected urine kidney injury biomarkers were independently associated with higher risk of HF, CVD events, and death in CRIC. Among the biomarkers examined, only KIM-1/Cr was associated with each outcome. Further work is needed to determine the utility of these biomarkers to improve risk prediction for these adverse outcomes.
BACKGROUND AND OBJECTIVES: CKD is an important risk factor for cardiovascular disease (CVD) and death. We investigated whether select urine kidney injury biomarkers were associated with higher risk of heart failure (HF), CVD, and death in persons with CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Urine kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin, liver fatty acid-binding protein, and N-acetyl-β-d-glucosaminidase were measured in urine of a subset of CRIC participants (n=2466). We used Cox proportional hazards regression to examine associations between these biomarkers indexed to urinary creatinine (Cr) and (1) HF, (2) a composite of atherosclerotic CVD events (myocardial infarction, ischemic stroke, or peripheral artery disease), and (3) all-cause death. RESULTS: At baseline, mean age of study participants was 59.5±10.8 years, 46% were women, and 34% had a self-reported history of any CVD. Median follow-up was 6.5 (interquartile range, 5.6-6.8) years. A total of 333 HF events, 282 atherosclerotic CVD events, and 440 deaths were observed during a median follow-up of 6.5 (interquartile range, 5.6-6.8) years. Those in the highest two quintiles of KIM-1/Cr levels had a higher risk of HF relative to the lowest quintile (quintile 5 versus quintile 1 adjusted hazard ratio [aHR] of 1.73 [95% confidence interval, 1.05 to 2.85]). N-acetyl-β-d-glucosaminidase/Cr was associated with HF in continuous analyses (aHR per log SD higher 1.18 [95% confidence interval, 1.01 to 1.38]). Only KIM-1/Cr was independently associated with atherosclerotic CVD events (aHR per log SD higher 1.21 [95% confidence interval, 1.02 to 1.41]), whereas both KIM-1/Cr (quintile 5 versus quintile 1 aHR of 1.56 [95% confidence interval, 1.06 to 2.31]) and neutrophil gelatinase-associated lipocalin/Cr (quintile 5 versus quintile 1 aHR of 1.82 [95% confidence interval, 1.19 to 2.8]) were associated with all-cause death. CONCLUSIONS: Selected urine kidney injury biomarkers were independently associated with higher risk of HF, CVD events, and death in CRIC. Among the biomarkers examined, only KIM-1/Cr was associated with each outcome. Further work is needed to determine the utility of these biomarkers to improve risk prediction for these adverse outcomes.
Authors: Raymond R Townsend; Amanda H Anderson; Jing Chen; Crystal A Gadebegku; Harold I Feldman; Jeffrey C Fink; Alan S Go; Marshall Joffe; Lisa A Nessel; Akinlolu Ojo; Daniel J Rader; Muredach P Reilly; Valerie Teal; Karen Teff; Jackson T Wright; Dawei Xie Journal: Am J Nephrol Date: 2011-04-27 Impact factor: 3.754
Authors: Johanna Helmersson-Karlqvist; Anders Larsson; Axel C Carlsson; Per Venge; Johan Sundström; Erik Ingelsson; Lars Lind; Johan Arnlöv Journal: Atherosclerosis Date: 2013-01-18 Impact factor: 5.162
Authors: Mark J Sarnak; Ronit Katz; Anne Newman; Tamara Harris; Carmen A Peralta; Prasad Devarajan; Michael R Bennett; Linda Fried; Joachim H Ix; Suzanne Satterfield; Eleanor M Simonsick; Chirag R Parikh; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121
Authors: Harold I Feldman; Lawrence J Appel; Glenn M Chertow; Denise Cifelli; Borut Cizman; John Daugirdas; Jeffrey C Fink; Eunice D Franklin-Becker; Alan S Go; L Lee Hamm; Jiang He; Tom Hostetter; Chi-Yuan Hsu; Kenneth Jamerson; Marshall Joffe; John W Kusek; J Richard Landis; James P Lash; Edgar R Miller; Emile R Mohler; Paul Muntner; Akinlolu O Ojo; Mahboob Rahman; Raymond R Townsend; Jackson T Wright Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: Nisha Bansal; Myra A Carpenter; Daniel E Weiner; Andrew S Levey; Marc Pfeffer; John W Kusek; Jianwen Cai; Lawrence G Hunsicker; Meyeon Park; Michael Bennett; Kathleen D Liu; Chi-Yuan Hsu Journal: J Am Soc Nephrol Date: 2015-11-04 Impact factor: 10.121
Authors: James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2009-06-18 Impact factor: 8.237
Authors: Ca Peralta; R Scherzer; C Grunfeld; A Abraham; Pc Tien; P Devarajan; M Bennett; Aw Butch; K Anastos; Mh Cohen; M Nowicki; A Sharma; Ma Young; Mj Sarnak; Cr Parikh; Mg Shlipak Journal: HIV Med Date: 2013-12-03 Impact factor: 3.180
Authors: Venkata S Sabbisetti; Sushrut S Waikar; Daniel J Antoine; Adam Smiles; Chang Wang; Abinaya Ravisankar; Kazumi Ito; Sahil Sharma; Swetha Ramadesikan; Michelle Lee; Rebeccah Briskin; Philip L De Jager; Thanh Thu Ngo; Mark Radlinski; James W Dear; Kevin B Park; Rebecca Betensky; Andrzej S Krolewski; Joseph V Bonventre Journal: J Am Soc Nephrol Date: 2014-06-05 Impact factor: 10.121
Authors: Tariq Ahmad; Keyanna Jackson; Veena S Rao; W H Wilson Tang; Meredith A Brisco-Bacik; Horng H Chen; G Michael Felker; Adrian F Hernandez; Christopher M O'Connor; Venkata S Sabbisetti; Joseph V Bonventre; F Perry Wilson; Steven G Coca; Jeffrey M Testani Journal: Circulation Date: 2018-01-19 Impact factor: 29.690
Authors: Alexandra K Lee; Ronit Katz; Vasantha Jotwani; Pranav S Garimella; Walter T Ambrosius; Alfred K Cheung; Lisa H Gren; Javier A Neyra; Henry Punzi; Kalani L Raphael; Michael G Shlipak; Joachim H Ix Journal: Hypertension Date: 2019-08-05 Impact factor: 10.190
Authors: Girish N Nadkarni; Kinsuk Chauhan; Veena Rao; Joachim H Ix; Michael G Shlipak; Chirag R Parikh; Steven G Coca Journal: Am J Kidney Dis Date: 2018-10-02 Impact factor: 8.860
Authors: Vasantha K Jotwani; Alexandra K Lee; Michelle M Estrella; Ronit Katz; Pranav S Garimella; Rakesh Malhotra; Dena E Rifkin; Walter Ambrosius; Barry I Freedman; Alfred K Cheung; Kalani L Raphael; Paul Drawz; Javier A Neyra; Suzanne Oparil; Henry Punzi; Michael G Shlipak; Joachim H Ix Journal: Am J Nephrol Date: 2019-04-02 Impact factor: 3.754
Authors: Melanie H Jacobson; Yinxiang Wu; Mengling Liu; Kurunthachalam Kannan; Adela Jing Li; Morgan Robinson; Bradley A Warady; Susan Furth; Howard Trachtman; Leonardo Trasande Journal: Environ Int Date: 2021-05-02 Impact factor: 13.352